ArticleBMC pediatrics2026
Clinical heterogeneity, genotype, and neurological outcomes in six Palestinian patients with ornithine transcarbamylase deficiency.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOrnithine transcarbamylase deficiency (OTCD) is the most common urea cycle disorder. This X-linked condition, mapped to Xp21.1, results from a deficiency of the mitochondrial enzyme ornithine transcarbamylase, which catalyzes a critical step in ureagenesis. Disease severity ranges from a complete enzymatic block, presenting as neonatal hyperammonemic coma with high mortality, to partial deficiencies that can cause life-threatening hyperammonemia at any age. PATIENTS AND
methodsThis report describes six patients diagnosed with OTCD, with ages ranging from 8 days to 17 years at the time of diagnosis. The onset of symptoms occurred at different ages, from just 2 days to 17 years. Two male patients experienced severe neonatal courses and, unfortunately, died from hyperammonemic coma shortly after birth. In contrast, four other patients (three males and one female) presented with symptoms later in life. Molecular analysis identified pathogenic variants in the OTC gene, which included four missense variants and one in-frame deletion. Notably, a recurrent variant was found in two individuals from unrelated families.
resultsThe cohort comprised six patients with two distinct clinical presentations. Two hemizygous males presented neonatally and progressed to severe hyperammonemic coma within the first days of life. The other four patients (3 males, 1 female) exhibited a late-onset form, with symptom onset ranging from infancy to 17 years. Their phenotypes were highly variable, encompassing acute hyperammonemic episodes and a chronic neurological course characterized by speech and motor delay, muscle cramps, and persistent toe-walking. Genetic analysis revealed five distinct pathogenic or likely pathogenic variants (four missense substitutions and one in-frame deletion). These were identified by whole-exome sequencing in five patients and by targeted Sanger sequencing in one patient.
conclusionsThis study highlights the molecular and phenotypic heterogeneity of OTCD and explores the correlation between genotype and phenotype. The manifestation of the disease in a heterozygous female suggests that skewed X-inactivation may serve as a potential pathogenic mechanism. The variation in age at symptom onset, alongside the genetic diversity observed, underscores the continuum between neonatal and late-onset OTCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.